利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.033 秒)

    Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample
    7.
    发明申请
    Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample 审中-公开
    用于测定样品中代谢物疾病生物标记物的清除标准化量的方法和方法

    公开(公告)号：US20160047829A1

    公开(公告)日：2016-02-18

    申请号：US14435952

    申请日：2013-10-16

    申请人： METANOMICS GMBH ,  REPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

    发明人： Jens Fuhrmann ,  Jenny Fischer ,  Regina Reszka ,  Hugo A Katus ,  Nobert Frey ,  Johanna Sigl ,  Tanja Weis

    IPC分类号： G01N33/92 ,  G01N33/64 ,  G01N33/50 ,  G01N33/62

    CPC分类号： G01N33/92 ,  G01N33/50 ,  G01N33/62 ,  G01N33/64 ,  G01N33/6896 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2560/00 ,  G01N2800/02 ,  G01N2800/042 ,  G01N2800/2814 ,  G01N2800/32 ,  G01N2800/325 ,  G01N2800/347

    摘要： The present invention relates to a method for determining a clearance normalized amount of a metabolite disease biomarker in a sample including the steps of (a) determining the amount of the disease biomarker in at least a first type of sample of a subject suspected to suffer from the disease, (b) determining the amount of a kidney function biomarker which correlates with the glomerular filtration rate (GFR) in the said at least first type of sample, and (c) determining a clearance normalized amount for the metabolite disease biomarker by normalizing the amount determined for the metabolite disease biomarker in step (a) to the amount of the kidney function biomarker determined in step (b). Moreover, the invention also relates to a method for diagnosing a disease in a subject suspected to suffer therefrom and to a device for determining a clearance normalized amount of a metabolite disease biomarker in a sample.

    摘要翻译： 本发明涉及一种用于确定样品中代谢物疾病生物标志物的清除标准化量的方法，包括以下步骤：（a）确定怀疑患有至少一种受试者的至少第一类样品的疾病生物标志物的量 所述疾病，（b）确定与所述至少第一类型样品中的肾小球滤过率（GFR）相关的肾功能生物标志物的量，和（c）通过归一化来测定代谢物疾病生物标志物的清除标准化量 在步骤（a）中为代谢物疾病生物标志物确定的量与步骤（b）中测定的肾功能生物标志物的量的量。 此外，本发明还涉及用于诊断疑似受试者的疾病的方法以及用于测定样品中代谢物疾病生物标志物的清除标准化量的装置。